日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

针对补体因子 H 的抗体 GT103 在难治性非小细胞肺癌中的应用:一项 1b 期剂量递增试验

Clarke Jeffrey M, Simon George R, Mamdani Hirva, Gu Lin, Herndon James E 2nd, Stinchcombe Thomas E, Ready Neal, Crawford Jeffrey, Sonpavde Guru, Balevic Stephen, Nixon Andrew B, Campa Michael, Gottlin Elizabeth B, Li Huihua, Saxena Ruchi, He You Wen, Antonia Scott, Patz Edward F Jr

Vps34 puts the 'e' in eTreg cells

Vps34 赋予 eTreg 细胞“e”的功能

Saxena, Ruchi; He, You-Wen

Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis

暂时中断阿特珠单抗和贝伐珠单抗治疗对晚期肝细胞癌患者生存的影响:一项IMbrave150分析

Xu, Xiao-Qian; Li, Wei-Ming; Shi, Li-Chen; Wang, Hao; Li, Shun; Huang, Cheng; You, Hong; Jia, Ji-Dong; He, You-Wen; Kong, Yuan-Yuan

Association of pre-diagnosis plasma proteomic contexture with overall survival of early- and late-stage colon cancer patients

诊断前血浆蛋白质组学特征与早期和晚期结肠癌患者总生存期的相关性

Li, Shun; Wang, Hao; Xu, Xiao-Qian; Li, Wei-Ming; You, Hong; Jia, Ji-Dong; He, You-Wen; Kong, Yuan-Yuan

Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials

CDK4/6抑制剂联合内分泌治疗治疗HR阳性/HER2-0和HER2低表达转移性乳腺癌的临床疗效:PALOMA-2和PALOMA-3试验的二次分析

Li, Huiyue; Wu, Yun; Zou, Haotian; Koner, Salil; Plichta, Jennifer K; Tolaney, Sara M; Zhang, Jian; He, You-Wen; Wei, Qingyi; Tang, Li; Zhang, Hui; Zhang, Baoshan; Guo, Yuanyuan; Chen, Xin; Li, Kan; Lian, Liyou; Ma, Fei; Luo, Sheng

Complement factor H: a novel innate immune checkpoint in cancer immunotherapy

补体因子H:癌症免疫疗法中的一种新型先天免疫检查点

Saxena, Ruchi; Gottlin, Elizabeth B; Campa, Michael J; Bushey, Ryan T; Guo, Jian; Patz, Edward F Jr; He, You-Wen

Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

靶向调控细胞死亡通路治疗癌症的有效策略:一项综合综述

Saxena, Ruchi; Welsh, Craig M; He, You-Wen

Bcl2l1 Deficiency in Osteoblasts Reduces the Trabecular Bone Due to Enhanced Osteoclastogenesis Likely through Osteoblast Apoptosis

成骨细胞中Bcl2l1的缺乏会因破骨细胞生成增强而减少骨小梁,这可能是通过成骨细胞凋亡实现的。

Moriishi, Takeshi; Kawai, Yosuke; Fukuyama, Ryo; Matsuo, Yuki; He, You-Wen; Akiyama, Haruhiko; Asahina, Izumi; Komori, Toshihisa

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C

胶质母细胞瘤的联合免疫疗法,包括树突状细胞癌疫苗、抗PD-1抗体和聚肌苷酸胞苷酸(poly I:C)。

Zhu, Ping; Li, Shi-You; Ding, Jin; Fei, Zhou; Sun, Sheng-Nan; Zheng, Zhao-Hui; Wei, Ding; Jiang, Jun; Miao, Jin-Lin; Li, San-Zhong; Luo, Xing; Zhang, Kui; Wang, Bin; Zhang, Kun; Pu, Su; Wang, Qian-Ting; Zhang, Xin-Yue; Wen, Gao-Liu; Liu, Jun O; August, John Thomas; Bian, Huijie; Chen, Zhi-Nan; He, You-Wen

Editorial: Editor's Pick 2021: Highlights in Cell Death and Survival

社论:2021年编辑精选:细胞死亡与存活领域的亮点

He, You-Wen; Walsh, Craig M